dc.contributor.author | Perciani, CT | |
dc.contributor.author | Sekhon, M | |
dc.contributor.author | Hundal, S | |
dc.contributor.author | Farah, B | |
dc.contributor.author | Ostrowski, MA | |
dc.contributor.author | Anzala, AO | |
dc.contributor.author | McKinnon, LR | |
dc.contributor.author | Jaoko, W | |
dc.contributor.author | MacDonald, KS | |
dc.date.accessioned | 2019-07-04T12:15:06Z | |
dc.date.available | 2019-07-04T12:15:06Z | |
dc.date.issued | 2018-09-08 | |
dc.identifier.citation | J Infect Dis. 2018 Sep 8;218(8):1210-1218. | en_US |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pubmed/29800309 | |
dc.identifier.uri | http://erepository.uonbi.ac.ke/handle/11295/106535 | |
dc.description.abstract | BACKGROUND:
Attenuated varicella zoster virus (VZV) is a promising vector for recombinant vaccines. Because human immunodeficiencyvirus (HIV) vaccines are believed to require mucosal immunogenicity, we characterized mucosal VZV-specific humoral immunity following VZVOka vaccination.
METHODS:
Adult Kenyan VZV-seropositive women (n = 44) received a single dose of the live zoster VZVOka vaccine. The anamnestic responses to the virus were followed longitudinally in both plasma and mucosal secretions using an in-house glycoprotein enzyme-linked immunosorbent assay and safety and reactogenicity monitored. VZV seroprevalence and baseline responses to the virus were also characterized in our cohorts (n = 288).
RESULTS:
Besides boosting anti-VZV antibody responses systemically, vaccination also boosted anti-VZV immunity in the cervicovaginal mucosa with a 2.9-fold rise in immunoglobulin G (P < .0001) and 1.6-fold rise in immunoglobulin A (IgA) (P = .004) from the time before immunization and 4 weeks postvaccination. Baseline analysis demonstrated high avidity antibodies at the gastrointestinal and genital mucosa of VZV-seropositive women. Measurement of VZV-specific IgA in saliva is a sensitive tool for detecting prior VZV infection.
CONCLUSIONS:
VZVOka vaccine was safe and immunogenic in VZV-seropositive adult Kenyan women. We provided compelling evidence of VZV ability to induce genital mucosa immunity. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Oxford Academic | en_US |
dc.title | Live Attenuated Zoster Vaccine Boosts Varicella Zoster Virus (VZV)-Specific Humoral Responses Systemically and at the Cervicovaginal Mucosa of Kenyan VZV-Seropositive Women. | en_US |
dc.type | Article | en_US |